Based on our data, applying JAK/stat3 inhibitors, either alone or in combination with anti‐PD‐L1 approach, may be an effective therapeutic approach to improve the efficacy of immunotherapy for prostate cancer. The gene discussed is STAT3; the disease is Familial prostate cancer.